‹ ›
MYP_082006
← PREVIOUS NEXT → BACK
Basic Information
SR9
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV
Antiviral ▸ Anti-Coronavirus ▸ Anti-SARS-CoV-2
Antiviral ▸ Anti-HIV
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition ▸ Fusion inhibitor
Enzyme modulation ▸ Enzyme inhibition ▸ Infection inhibition
Enzyme modulation ▸ Enzyme inhibition ▸ Protease inhibition
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor
Membrane / Ion-channel modulation ▸ Sodium channel modulation ▸ Sodium channel inhibitor cross
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
35 amino acids
C168H287N47O58
Standard
Sequence
ISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
Physicochemical Analysis
3893.36 Da
4.36
-3.23
-3.44
-0.0922
-0.08
0.70
0.02
43.51
142.00
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1752.78
-18.20
57.0
55.0
139.0
273.0
0.0
41.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0274020 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
None
PEG8-K(Chol)
PEG8-K(Chol)
Bio-Activity Profile
Antiviral Fusion inhibition
inhibition of pseudovirus infection in Huh-7 cells
0.0215 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperSARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. | Zhu Y, Yu D, Hu Y, Wu T, Chong H, He Y. | Signal Transduct Target Ther. 2021 Aug 3;6(1):294. | DOI:10.1038/s41392-021-00698-x | PMID:34344868 PMID34344868 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/34344868/
RECORD: Rec_0274986 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Anti-SARS-CoV-2
Vesicular Stomatitis Virus (VSV):inhibition of Pseudovirus (PsV) infection in 293T/ACE2 cells
50 μM
IC50
PMID17942557;18442051;32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17942557/
RECORD: Rec_0286747 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Neutralization
neutralizing activities against pseudotype HCoV-19 virus
0.32 μM
EC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperStructural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry. | Sun H, Li Y, Liu P, Qiao C, Wang X, Wu L, Liu K, Hu Y, Su C, Tan S, Zou S, Wu G, Yan J, Gao GF, Qi J, Wang Q. | Emerg Microbes Infect. 2020 Dec;9(1):1238-1241. | DOI:10.1080/22221751.2020.1770631 | PMID:32482145 PMID32482145 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32482145/
RECORD: Rec_0288432 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-SARS-CoV Fusion inhibition
SARS-CoV | VERO-E6 cells
0.005 μM
EC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperHeptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. | Ujike M, Nishikawa H, Otaka A, Yamamoto N, Yamamoto N, Matsuoka M, Kodama E, Fujii N, Taguchi F. | J Virol. 2008 Jan;82(1):588-92. | DOI:10.1128/JVI.01697-07 | PMID:17942557 PMID17942557 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/17942557/
RECORD: Rec_0301044 VERIFIED: YES
Provenance & Taxonomy
Severe acute respiratory syndrome coronavirus 2 [Virus]
HR2-derived fusion inhibitor
2697049
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
Severe acute respiratory syndrome coronavirus 2
50 μM
IC50
PaperDesign of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity PMID32376627 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/32376627/
FIRST PREV 1 ... 6 7 8 9 10 ... 12 NEXT LAST
Showing 5 records on this page · Page 8 of 12